Mario Uccello

Bath, ENG BA13NG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Incorporating Metastatic Disease Burden into Prognostic Assessment in Metastatic Castration-Resistant Prostate Cancer: The MIRA Score.

Incorporating Metastatic Disease Burden into Prognostic Assessment in Metastatic Castration-Resistant Prostate Cancer: The MIRA Score.

Journal: Cancers
Published: July 16, 2026

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA.

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA.

Journal: Cancers
Published: July 06, 2026

Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study.

Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study.

Journal: Current oncology (Toronto, Ont.)
Published: April 25, 2026

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.

Journal: Therapeutic advances in medical oncology
Published: April 05, 2023

Melanoma-the therapeutic considerations in the clinical practice.

Melanoma-the therapeutic considerations in the clinical practice.

Journal: Annals of palliative medicine
Published: December 23, 2022

Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence.

Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence.

Journal: Annals of palliative medicine
Published: November 26, 2022

Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?

Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?

Journal: Annals of translational medicine
Published: January 25, 2021

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?

Journal: Annals of translational medicine
Published: January 25, 2021

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.

Journal: Annals of translational medicine
Published: January 25, 2021

Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches.

Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches.

Journal: Annals of translational medicine
Published: January 25, 2021

Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.

Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.

Journal: Clinical genitourinary cancer
Published: February 23, 2019

Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).

Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).

Journal: Current oncology (Toronto, Ont.)
Published: March 07, 2018
Showing 1-12 of 29

Last Updated: 09/26/2026